Source link : https://newshealth.biz/health-news/esketamine-monotherapy-safe-effective-for-trd-phase-4-data/
TOPLINE: Esketamine monotherapy was associated with significantly alleviated symptoms of treatment-resistant depression (TRD) at day 28 compared to placebo in a new phase 4 trial. The research extends findings from an earlier trial that served as the basis for the January FDA approval of an expanded indication for esketamine alone in patients with TRD. METHODOLOGY: […]
The post Esketamine Monotherapy Safe, Effective for TRD: Phase 4 Data first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-15 09:17:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8